Bayer

Bayer AG is a German life-sciences company. The 2018 Monsanto acquisition made it a leader in seeds and glyphosate alongside its crop-chemical and pharmaceutical businesses. Authorities cleared the deal only after large divestitures to BASF.

The competitive fear was a combined firm that could tie a patented trait, the seed, and the chemical that works with that trait. Farmers who want the trait take the bundle. Generic chemical makers lose the complementary sale.

Trait licenses to other seed companies are a bottleneck. Terms that restrict stacking a rival's trait, or that tie rebates to exclusive use, are the vertical restraints in this market. They are technical and they decide what gets planted.

Pharmaceuticals are a separate competition world of patents and pay-for-delay. Bayer participates there too. The Monsanto deal is the file that defines the company in this library.

The Monsanto merger was cleared with divestitures, not blocked. Those divestitures are the remedy to watch.

Trait-chemical bundles are a tying structure in seeds.

Licensing terms decide whether independent seed companies can offer the same genetics.

Data from digital farming platforms can advantage the trait owner over a generic seller.

Farmers choose among fewer independent trait stacks than before the merger.

Food prices are several steps downstream. The direct customer is the farm, not the grocery shopper.